LENZ Therapeutics Inc
LENZ27.930USD
-1.790-6.02%
종가 11/03, 16:00（ET）시세는 15분 지연됩니다
796.01M시가총액
손실P/E TTM
자세한 내용은 LENZ Therapeutics Inc 회사
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
LENZ Therapeutics Inc 정보
종목 코드 LENZ
회사 이름LENZ Therapeutics Inc
상장일Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
직원 수42
유형Ordinary Share
회계 연도 종료Jun 25
주소- -
도시- -
증권 거래소NASDAQ Global Select Consolidated
국가- -
우편 번호- -
전화- -
웹사이트- -
종목 코드 LENZ
상장일Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
LENZ Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Aug 24
마지막 업데이트: Sun, Aug 24
주주
주주 유형
주주
주주
비율
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
기타
49.72%
주주
주주
비율
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
기타
49.72%
주주 유형
주주
비율
Venture Capital
38.62%
Hedge Fund
27.55%
Investment Advisor
23.95%
Investment Advisor/Hedge Fund
14.32%
Individual Investor
2.73%
Research Firm
2.25%
Bank and Trust
0.14%
Pension Fund
0.06%
Insurance Company
0.02%
기관 주식 보유
마지막 업데이트: Sun, Oct 5
마지막 업데이트: Sun, Oct 5
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
261
30.52M
107.02%
+1.08M
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
Adage Capital Management, L.P.
1.12M
3.94%
+585.00K
+108.79%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Sectoral Asset Management Inc.
977.25K
3.43%
--
--
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Nov 2
마지막 업데이트: Sun, Nov 2
이름
비율
SPDR S&P Pharmaceuticals ETF
1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.28%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
0.43%
iShares U.S. Pharmaceuticals ETF
0.34%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Biotechnology ETF
0.11%
더 보기
SPDR S&P Pharmaceuticals ETF
비율1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율1.28%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
비율0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.43%
iShares U.S. Pharmaceuticals ETF
비율0.34%
iShares Micro-Cap ETF
비율0.16%
Invesco Nasdaq Biotechnology ETF
비율0.14%
ProShares Ultra Nasdaq Biotechnology
비율0.14%
iShares Biotechnology ETF
비율0.11%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
날짜
유형
비율
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
